TG Therapeutics (TGTX) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free TGTX Stock Alerts $14.25 +0.15 (+1.06%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)markets.businessinsider.com - April 23 at 7:42 PMJPMorgan Chase & Co. Reiterates "Overweight" Rating for TG Therapeutics (NASDAQ:TGTX)americanbankingnews.com - April 20 at 2:26 AMTG Therapeutics (NASDAQ:TGTX) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - April 20 at 2:26 AMTG Therapeutics (NASDAQ:TGTX) Stock Rating Reaffirmed by LADENBURG THALM/SH SHamericanbankingnews.com - April 20 at 1:30 AMTG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%marketbeat.com - April 18 at 4:55 PMTG Therapeutics (NASDAQ:TGTX) Earns "Overweight" Rating from JPMorgan Chase & Co.marketbeat.com - April 18 at 2:21 PMTG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 18 at 7:30 AMTG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosisglobenewswire.com - April 18 at 7:00 AMTG Therapeutics: The Cloud Over Briumviseekingalpha.com - April 17 at 10:24 AMTG Posts Gains on Results of MS Drug Testmsn.com - April 15 at 1:50 PMTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 15 at 7:30 AMTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 15 at 7:30 AMTG Therapeutics Breaks Below 200-Day Moving Average - Notable for TGTXnasdaq.com - April 14 at 8:16 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Brokeragesamericanbankingnews.com - April 14 at 2:12 AMTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - April 14 at 2:12 AMTG Therapeutics: BRIUMVI Development Could Lead To Great Resultsseekingalpha.com - April 12 at 8:00 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from Brokeragesmarketbeat.com - March 20 at 3:41 AMIs TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?finance.yahoo.com - March 19 at 10:29 AMTg therapeutics director sells shares worth over $79kinvesting.com - March 17 at 9:24 AMTGTX Mar 2024 20.500 callfinance.yahoo.com - March 16 at 1:08 PMTGTX Mar 2024 16.500 putfinance.yahoo.com - March 16 at 1:08 PMTGTX Apr 2024 19.500 callfinance.yahoo.com - March 16 at 3:07 AMTGTX Apr 2024 11.000 putfinance.yahoo.com - March 16 at 3:07 AMTGTX Apr 2024 23.000 callfinance.yahoo.com - March 15 at 5:06 PMTGTX Apr 2024 16.000 putfinance.yahoo.com - March 15 at 5:06 PMJacobs Levy Equity Management Inc. Purchases 145,667 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 15 at 4:16 AMLaurence N. Charney Sells 22,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stockinsidertrades.com - March 14 at 9:39 AMTG Therapeutics (NASDAQ:TGTX) Shares Down 3.9% marketbeat.com - March 8 at 1:45 PMTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - March 8 at 7:30 AMFmr LLC Lowers Position in TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 8 at 4:25 AMValidea Detailed Fundamental Analysis - TGTXnasdaq.com - March 6 at 4:14 PMTGTX Mar 2024 19.500 callfinance.yahoo.com - March 3 at 6:20 PMTGTX Mar 2024 18.000 putfinance.yahoo.com - March 3 at 6:20 PMSchonfeld Strategic Advisors LLC Has $11.43 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 3 at 8:20 AM683 Capital Management LLC Invests $11.29 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 1 at 10:35 AMTG Therapeutics: Briumvi Growth Story Appears Intactseekingalpha.com - March 1 at 8:50 AMBrokers Issue Forecasts for TG Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:TGTX)marketbeat.com - March 1 at 8:45 AMTG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forumglobenewswire.com - March 1 at 7:30 AMTG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 29 at 11:42 AMHC Wainwright Comments on TG Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:TGTX)marketbeat.com - February 29 at 9:29 AMTG Therapeutics (NASDAQ:TGTX) Price Target Raised to $13.00 at The Goldman Sachs Groupmarketbeat.com - February 29 at 8:33 AMTG Therapeutics price target raised by $1 at Goldman Sachs, here's whyrealmoney.thestreet.com - February 28 at 10:58 PMQ4 2023 TG Therapeutics Inc Earnings Callfinance.yahoo.com - February 28 at 10:58 PMWhy Is Multiple Sclerosis-Focused TG Therapeutics Stock Trading Higher Today?msn.com - February 28 at 5:58 PMTG Therapeutics Inc (TGTX) Announces Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 28 at 12:57 PMTG Therapeutics jumps after second consecutive quarterly beatmsn.com - February 28 at 12:57 PMTG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?finance.yahoo.com - February 28 at 12:57 PMTG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)marketbeat.com - February 28 at 11:27 AMHC Wainwright Equities Analysts Boost Earnings Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - February 28 at 8:23 AMTG Therapeutics GAAP EPS of -$0.09 beats by $0.02, revenue of $40M misses by $0.06Mmsn.com - February 28 at 7:56 AM Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now TGTX Media Mentions By Week TGTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼0.050.45▲Average Medical News Sentiment TGTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼125▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Rocket Pharmaceuticals News Dyne Therapeutics News Keros Therapeutics News Arvinas News Maravai LifeSciences News Rhythm Pharmaceuticals News Vera Therapeutics News Amphastar Pharmaceuticals News Merus News Geron News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
